Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.320
+0.020 (1.54%)
At close: May 8, 2026, 4:00 PM EDT
1.310
-0.010 (-0.76%)
After-hours: May 8, 2026, 7:42 PM EDT
Cardiol Therapeutics Employees
Cardiol Therapeutics had 18 employees as of December 31, 2024. The number of employees increased by 12 or 200.00% compared to the previous year.
Employees
18
Change
12
Growth
200.00%
Revenue / Employee
n/a
Profits / Employee
-$1,370,286
Market Cap
147.10M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 18 | - | - |
| Dec 31, 2018 | 6 | - | - |
| Sep 30, 2018 | 8 | - | - |
| Jun 30, 2018 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Organigram Global | 1,137 |
| Aurora Cannabis | 1,073 |
| Organogenesis Holdings | 854 |
| Lifecore Biomedical | 382 |
| Anika Therapeutics | 235 |
| Alpha Teknova | 158 |
| Journey Medical | 58 |
| Assertio Holdings | 53 |
CRDL News
- 2 days ago - Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association - PRNewsWire
- 11 days ago - Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clinical Sites - GuruFocus
- 11 days ago - Cardiol Therapeutics expands U.S. MAVERIC Phase III trial network - TheFly
- 11 days ago - Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program - PRNewsWire
- 25 days ago - Cardiol Therapeutics Transcript: Study result - Transcripts
- 25 days ago - Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart - Newsfile Corp
- 4 weeks ago - Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News - GuruFocus
- 5 weeks ago - Cardiol Therapeutics Announces Year-End 2025 Update on Operations - Newsfile Corp